Skip Nav Destination
The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease
Clin Sci (Lond) (2022) 136 (12): 1005–1017.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
- Yu Sun
- Mingzhu Wang
International Urology and Nephrology (2025) 57 (8): 2567.
- Ruoqi Liu
- Zhuomin Qu
- Yizhuo Feng
- Lu Bai
- Xueqian Liu
- Xuemei Fan
- Xiaoqi Liu
- Lingxia Zhao
Journal of Diabetes and its Complications (2025) 39 (4): 108981.
- Gregory Fettweis
- Thomas A. Johnson
- Brian Almeida‐Prieto
- Julián Weller‐Pérez
- Diego M. Presman
- Gordon L. Hager
- Diego Alvarez de la Rosa
Protein Science (2024) 33 (3)
- Mustafa Arici
- Bulent Altun
- Mustafa Araz
- Aysegul Atmaca
- Tevfik Demir
- Tevfik Ecder
- Galip Guz
- Dilek Gogas Yavuz
- Alaattin Yildiz
- Temel Yilmaz
Frontiers in Medicine (2024) 11
- Subo Dey
- Jasmine Garg
- Andy Wang
- Eva Holzner
- William H. Frishman
- Wilbert S. Aronow
Cardiology in Review (2024) 32 (3): 285.
- Yiyi Jin
- Miao Fan
- Xiaomeng Zheng
- Suyan Zhu
Expert Opinion on Drug Safety (2024) 1.
- Xiaoming Xu
- Jing Feng
- Yuying Cui
- Pingjiang Li
- Jianjun Dong
- Lin Liao
Journal of Diabetes (2024) 16 (6)
- Sophie Girerd
- Matthieu Soulie
- Jonatan Barrera-Chimal
- Frédéric Jaisser
médecine/sciences (2023) 39 (4): 335.
- Vladimir V. Salukhov
- Minara S. Shamkhalova
- Alla V. Duganova
Terapevticheskii arkhiv (2023) 95 (3): 261.
- Wataru Fujii
- Shigeru Shibata
International Journal of Molecular Sciences (2023) 24 (9): 7719.
